Cargando…

Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy

An increasing amount of evidence has highlighted the critical roles that copy number variants play in cancer progression. Here, we systematically analyzed the copy number alterations and differentially transcribed genes. Integrative analysis of the association between copy number variants and differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Gaochao, Mao, Qixing, Yu, Decai, Zhang, Yi, Qiu, Mantang, Dong, Gaoyue, Chen, Qiang, Xia, Wenjie, Wang, Jie, Xu, Lin, Jiang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294420/
https://www.ncbi.nlm.nih.gov/pubmed/28169357
http://dx.doi.org/10.1038/srep42060
_version_ 1782505237651652608
author Dong, Gaochao
Mao, Qixing
Yu, Decai
Zhang, Yi
Qiu, Mantang
Dong, Gaoyue
Chen, Qiang
Xia, Wenjie
Wang, Jie
Xu, Lin
Jiang, Feng
author_facet Dong, Gaochao
Mao, Qixing
Yu, Decai
Zhang, Yi
Qiu, Mantang
Dong, Gaoyue
Chen, Qiang
Xia, Wenjie
Wang, Jie
Xu, Lin
Jiang, Feng
author_sort Dong, Gaochao
collection PubMed
description An increasing amount of evidence has highlighted the critical roles that copy number variants play in cancer progression. Here, we systematically analyzed the copy number alterations and differentially transcribed genes. Integrative analysis of the association between copy number variants and differential gene expression suggested that copy number variants will lead to aberrant expression of the corresponding genes. We performed a KEGG pathway and GO analysis, which revealed that cell cycle may have an effective role in the progression of esophageal cancer. FAM60A was then screened out as a potential prognostic factor through survival analysis and correlation analysis with clinical-pathological parameters. We subsequently showed that silencing of FAM60A could inhibit esophageal carcinoma tumor cell growth, migration and invasion in vitro. Through the bioinformatic analysis, we predict that FAM60A may act as a transcriptional factor to regulate genes that are correlated with each cell cycle. In summary, we comprehensively analyzed copy number segments and transcriptional expression profiles, which provided a novel approach to identify clinical biomarkers and therapeutic targets of esophageal carcinoma.
format Online
Article
Text
id pubmed-5294420
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-52944202017-02-10 Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy Dong, Gaochao Mao, Qixing Yu, Decai Zhang, Yi Qiu, Mantang Dong, Gaoyue Chen, Qiang Xia, Wenjie Wang, Jie Xu, Lin Jiang, Feng Sci Rep Article An increasing amount of evidence has highlighted the critical roles that copy number variants play in cancer progression. Here, we systematically analyzed the copy number alterations and differentially transcribed genes. Integrative analysis of the association between copy number variants and differential gene expression suggested that copy number variants will lead to aberrant expression of the corresponding genes. We performed a KEGG pathway and GO analysis, which revealed that cell cycle may have an effective role in the progression of esophageal cancer. FAM60A was then screened out as a potential prognostic factor through survival analysis and correlation analysis with clinical-pathological parameters. We subsequently showed that silencing of FAM60A could inhibit esophageal carcinoma tumor cell growth, migration and invasion in vitro. Through the bioinformatic analysis, we predict that FAM60A may act as a transcriptional factor to regulate genes that are correlated with each cell cycle. In summary, we comprehensively analyzed copy number segments and transcriptional expression profiles, which provided a novel approach to identify clinical biomarkers and therapeutic targets of esophageal carcinoma. Nature Publishing Group 2017-02-07 /pmc/articles/PMC5294420/ /pubmed/28169357 http://dx.doi.org/10.1038/srep42060 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Dong, Gaochao
Mao, Qixing
Yu, Decai
Zhang, Yi
Qiu, Mantang
Dong, Gaoyue
Chen, Qiang
Xia, Wenjie
Wang, Jie
Xu, Lin
Jiang, Feng
Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy
title Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy
title_full Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy
title_fullStr Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy
title_full_unstemmed Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy
title_short Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy
title_sort integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294420/
https://www.ncbi.nlm.nih.gov/pubmed/28169357
http://dx.doi.org/10.1038/srep42060
work_keys_str_mv AT donggaochao integrativeanalysisofcopynumberandtranscriptionalexpressionprofilesinesophagealcancertoidentifyanoveldrivergenefortherapy
AT maoqixing integrativeanalysisofcopynumberandtranscriptionalexpressionprofilesinesophagealcancertoidentifyanoveldrivergenefortherapy
AT yudecai integrativeanalysisofcopynumberandtranscriptionalexpressionprofilesinesophagealcancertoidentifyanoveldrivergenefortherapy
AT zhangyi integrativeanalysisofcopynumberandtranscriptionalexpressionprofilesinesophagealcancertoidentifyanoveldrivergenefortherapy
AT qiumantang integrativeanalysisofcopynumberandtranscriptionalexpressionprofilesinesophagealcancertoidentifyanoveldrivergenefortherapy
AT donggaoyue integrativeanalysisofcopynumberandtranscriptionalexpressionprofilesinesophagealcancertoidentifyanoveldrivergenefortherapy
AT chenqiang integrativeanalysisofcopynumberandtranscriptionalexpressionprofilesinesophagealcancertoidentifyanoveldrivergenefortherapy
AT xiawenjie integrativeanalysisofcopynumberandtranscriptionalexpressionprofilesinesophagealcancertoidentifyanoveldrivergenefortherapy
AT wangjie integrativeanalysisofcopynumberandtranscriptionalexpressionprofilesinesophagealcancertoidentifyanoveldrivergenefortherapy
AT xulin integrativeanalysisofcopynumberandtranscriptionalexpressionprofilesinesophagealcancertoidentifyanoveldrivergenefortherapy
AT jiangfeng integrativeanalysisofcopynumberandtranscriptionalexpressionprofilesinesophagealcancertoidentifyanoveldrivergenefortherapy